This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

THOMAS D. JOHNSON, MD

Arch Intern Med. 1966;117(2):237-241.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE DEVELOPMENT of methysergide (Sansert) for the management of individuals with frequently recurring vascular headache has been a welcome adjunct to their care. This agent has the property of preventing or decreasing both the vasoconstrictor phase as well as the vasodilator phase responsible for the pain of migraine and allied head pains.¹ It has been used, therefore, as prophylactic therapy for individuals with frequently recurring headaches. The drug is usually well tolerated, side effects ordinarily being transient and mild, including nausea, giddiness or dizziness, epigastric distress, insomnia, difficulty concentrating, and limb pains.^2-9 Infrequent reports have occurred which raise the question of vasospastic phenomena, such as the development of intermittent claudication and cramping extremity pains. Acute peripheral ischemic reactions that have required five or more days to subside have occurred in a few. In some of the more severe reactions, there has been concomitant use of other vasoconstricting . . . [Full Text PDF of this Article]

Author Affiliations
ALBANY, GA

Footnotes
Received for publication May 18, 1965; accepted Oct 22.

Dr. Johnson is in private practice.

Reprint requests to 910 N Jefferson St, Albany, Ga 31705.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?